Centessa Pharmaceuticals GAAP EPS of -$0.57

Nov. 10, 2022 9:23 AM ETCentessa Pharmaceuticals plc (CNTA)By: Urvi Shah, SA News Editor
  • Centessa Pharmaceuticals press release (NASDAQ:CNTA): Q3 GAAP EPS of -$0.57.
  • Cash and Cash Equivalents: $444.8 million as of September 30, 2022, 
  • Research & Development Expenses: $36.7 million for the quarter ended September 30, 2022, compared to $25.9 million for the quarter ended September 30, 2021.
  • General & Administrative Expenses: $12.3 million for the quarter ended September 30, 2022, compared to $12.5 million the quarter ended September 30, 2021.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.